$1.54 EPS Expected for Icon Plc (ICLR) This Quarter

Equities analysts expect Icon Plc (NASDAQ:ICLR) to announce $1.54 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Icon’s earnings, with estimates ranging from $1.53 to $1.56. Icon reported earnings of $1.35 per share in the same quarter last year, which would indicate a positive year over year growth rate of 14.1%. The firm is expected to announce its next quarterly earnings results on Thursday, October 25th.

On average, analysts expect that Icon will report full year earnings of $6.08 per share for the current fiscal year, with EPS estimates ranging from $6.06 to $6.11. For the next year, analysts forecast that the company will post earnings of $6.82 per share, with EPS estimates ranging from $6.60 to $7.00. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Icon.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, July 25th. The medical research company reported $1.31 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by ($0.17). Icon had a return on equity of 26.35% and a net margin of 13.69%. The firm had revenue of $641.60 million for the quarter, compared to analyst estimates of $618.64 million. During the same quarter last year, the company earned $1.34 earnings per share. The company’s quarterly revenue was up 48.9% compared to the same quarter last year.

Several equities research analysts have recently weighed in on ICLR shares. Robert W. Baird increased their price objective on shares of Icon from $154.00 to $157.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 11th. Jefferies Financial Group increased their price objective on shares of Icon to $150.00 and gave the stock a “buy” rating in a research report on Friday, June 1st. Mizuho set a $146.00 price objective on shares of Icon and gave the stock a “hold” rating in a research report on Monday, August 6th. Credit Suisse Group increased their price objective on shares of Icon from $131.00 to $144.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 19th. Finally, BidaskClub upgraded shares of Icon from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Icon presently has a consensus rating of “Buy” and an average target price of $146.22.

Shares of ICLR traded down $0.58 during trading hours on Monday, hitting $149.67. 85,900 shares of the stock were exchanged, compared to its average volume of 255,907. Icon has a fifty-two week low of $101.22 and a fifty-two week high of $151.86. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.28. The stock has a market cap of $8.13 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 2.15 and a beta of 0.35.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Marietta Investment Partners LLC boosted its stake in Icon by 18.3% during the second quarter. Marietta Investment Partners LLC now owns 2,472 shares of the medical research company’s stock worth $328,000 after acquiring an additional 382 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Icon by 1.9% during the second quarter. Fisher Asset Management LLC now owns 21,316 shares of the medical research company’s stock worth $2,825,000 after acquiring an additional 400 shares in the last quarter. Cambiar Investors LLC boosted its stake in Icon by 9.9% during the second quarter. Cambiar Investors LLC now owns 4,498 shares of the medical research company’s stock worth $596,000 after acquiring an additional 405 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in Icon by 0.5% during the second quarter. CIBC Private Wealth Group LLC now owns 80,342 shares of the medical research company’s stock worth $10,648,000 after acquiring an additional 405 shares in the last quarter. Finally, Comerica Bank boosted its stake in Icon by 9.1% during the second quarter. Comerica Bank now owns 5,872 shares of the medical research company’s stock worth $806,000 after acquiring an additional 490 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply